Theriva Biologics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $5.3 million for the six-month period and held cash and cash equivalents of $11.3 million as of June 30, 2026, providing a runway into Q1 2027. General and administrative expenses decreased to $2.0 million from $11.2 million in the prior year period, primarily due to a $9.2 million reduction in fair value adjustments for contingent consideration related to VIRAGE Phase 2b trial results. Research and development expenses fell to $1.3 million from $2.0 million. The company dosed the first patients in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 for metastatic pancreatic ductal adenocarcinoma, with enrollment expected to complete in H2 2026 and initial data anticipated by Q3 2027. Theriva Biologics is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.

Theriva Biologics announced the dosing of the first patient in the VIRAGE2 Phase 2a clinical trial on August 6, 2026. This proof-of-concept study evaluates more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) combined with standard-of-care gemcitabine/nab-paclitaxel chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients. Enrollment is expected to complete in the second half of 2026, with initial pharmacodynamic and safety data anticipated by Q3 2027. The trial aims to refine the dosing regimen for a potential pivotal Phase 3 study based on positive survival signals observed in the prior VIRAGE Phase 2b trial. Theriva Biologics is a clinical-stage biotechnology company developing therapeutics, including the oncolytic adenovirus VCN-01, to treat cancer and related diseases.

On July 7, 2026, Theriva Biologics announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) authorized the initiation of the VIRAGE2 clinical trial. This Phase IIa, single-arm, open-label study will evaluate the feasibility of administering at least three doses of zabilugene almadenorepvec (VCN-01) every two months in combination with standard-of-care chemotherapy for patients with newly-diagnosed metastatic pancreatic cancer. The trial follows a 112-patient Phase 2b study where two doses of VCN-01 showed improved overall survival and progression-free survival. Results from VIRAGE2 will inform the dosing regimen for a potential future Phase 3 pivotal trial. The company is a biotechnology firm developing therapies for cancer.

Theriva Biologics, Inc. announced the publication of Phase 1 clinical trial results for VCN-01 in Head & Neck Squamous Cell Carcinoma (HNSCC) in the journal Clinical Cancer Research. The trial, involving 20 patients, showed median overall survival of 15.5 months in the sequential Arm II LD and 17.3 months in the sequential Arm II HD. Results showed increased stroma-degrading enzyme PH20 and CD8 upregulation, implying increased tumor infiltration with activated cytotoxic T cells. Theriva Biologics, Inc. is a biotechnology company focused on oncolytic virotherapy.</h2>